Dashboard
Manage Tickers

ERASErasca, Inc.

Nasdaq erasca.com


$ 2.33 $ 0.10 (4.49 %)    

Thursday, 27-Jun-2024 14:41:08 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.54 $ 0.55 (0.12 %)
DIA $ 390.29 $ -0.51 (-0.13 %)
SPY $ 544.68 $ -0.80 (-0.15 %)
TLT $ 93.55 $ 0.12 (0.13 %)
GLD $ 214.81 $ 0.10 (0.05 %)
$ 2.2
$ 2.22
$ 2.32 x 800
$ 2.33 x 1,306
$ 2.22 - $ 2.37
$ 1.51 - $ 2.97
3,260,524
na
332.56M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-26-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

erasca-initiates-seacraft-2-pivotal-phase-3-trial-evaluating-naporafenib-plus-trametinib-in-patients-with-nras-mutant-melanoma
Erasca Initiates SEACRAFT-2 Pivotal Phase ...
06/18/2024 12:05:36

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and h...

goldman-sachs-maintains-buy-on-erasca-lowers-price-target-to-4
Goldman Sachs Maintains Buy on Erasca, Low...
05/28/2024 15:40:09

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $7 to $4.

elf-beauty-posts-upbeat-earnings-joins-nvidia-liveramp-holdings-borr-drilling-and-other-big-stocks-moving-higher-on-thursday
e.l.f. Beauty Posts Upbeat Earnings, Joins...
05/23/2024 14:26:28

15m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggressively-buying
$1.5M Bet On This Healthcare Stock? Check ...
05/23/2024 12:47:33

hc-wainwright--co-maintains-buy-on-erasca-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on Erasc...
05/20/2024 10:28:33

HC Wainwright & Co. analyst Andres Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from ...

dxc-technology-issues-weak-outlook-joins-take-two-interactive-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
DXC Technology Issues Weak Outlook, Joins ...
05/17/2024 09:34:01

reported-earlier-erasca-prices-underwritten-offering-of-86486486-common-stock-at-185share
Reported Earlier, Erasca Prices Underwritt...
05/17/2024 05:23:44

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable sec...

reported-earlier-erasca-entered-into-exclusive-license-agreements-for-two-preclinical-ras-programs
Reported Earlier, Erasca Entered Into Excl...
05/17/2024 05:19:50

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class prof...

erasca-plans-to-deprioritize-eras-007-eras-801-programs-to-discontinue-its-existing-internal-eras-4-pan-kras-program
Erasca Plans To Deprioritize ERAS-007, ERA...
05/16/2024 20:36:18

The Company will deprioritize the ERAS-007 program as the Company believes the clinical efficacy data from the HERKULES-3 clini...

erasca-reveals-reduction-in-workforce-by-18-in-connection-with-strategic-reprioritization-primarily-affecting-employees-working-in-drug-discovery-functions-or-on-deprioritized-programs---filing
Erasca Reveals Reduction In Workforce By ~...
05/16/2024 20:29:14

https://www.sec.gov/ix?doc=/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm

hc-wainwright--co-reiterates-buy-on-erasca-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Eras...
05/09/2024 11:40:32

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

erasca-q1-eps-023-misses-022-estimate
Erasca Q1 EPS $(0.23) Misses $(0.22) Estimate
05/08/2024 21:04:28

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/19/2024 12:08:38

goldman-sachs-maintains-buy-on-erasca-raises-price-target-to-7
Goldman Sachs Maintains Buy on Erasca, Rai...
04/02/2024 16:16:19

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.

hc-wainwright--co-reiterates-buy-on-erasca-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Eras...
03/28/2024 10:13:44

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

reported-earlier-erasca-announced-45m-oversubscribed-private-placement-financing
Reported Earlier, Erasca Announced $45M Ov...
03/28/2024 05:43:13

Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, d...

erasca-q4-eps-020-beats-021-estimate
Erasca Q4 EPS $(0.20) Beats $(0.21) Estimate
03/27/2024 20:05:24

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.7...

capital-one-initiates-coverage-on-erasca-with-overweight-rating-announces-price-target-of-8
Capital One Initiates Coverage On Erasca w...
03/11/2024 14:00:21

Capital One analyst Naureen Quibria initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price ...

Core News & Articles
Erasca Announces Two Clinical Trial Collab...
02/14/2024 13:10:16

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initia...

b-of-a-securities-downgrades-erasca-to-neutral-lowers-price-target-to-6
B of A Securities Downgrades Erasca to Neu...
01/05/2024 14:13:58

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Neutral and lowers the price target fro...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)